Subscribe
Share
Share
Embed
A two-year trial finds fish oil doesn't improve cognition; L'Oréal's CEO confirms GLP-1 drugs are reshaping beauty spending; Cymbiotika targets ingestible beauty.
A landmark clinical trial just gutted fish oil's brain health story — and L'Oréal's CEO confirmed GLP-1 drugs are formally reshaping consumer spending. Two credibility moments supplement and health brands can't ignore.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Plenty to dig into today.
Klara: We've got a bruising two-year trial that puts fish oil's brain health claims under serious pressure.
Marco: Italy's ad watchdog has taken aim at a magnesium supplement brand — and the message lands well beyond Italy.
Klara: Cymbiotika is moving into beauty supplements off the back of 200 million liposomal sachets sold.
Marco: And L'Oréal's CEO says GLP-1 drugs are reshaping how people buy beauty and skincare.
Klara: Let's get into it.
Marco: Millions of people take fish oil every day hoping to protect their brain. A major new clinical trial suggests that might not be working.
Marco: Fish oil is one of the biggest supplement categories in Europe and globally. Brain health is one of its most powerful marketing angles. Brands have built entire product lines around the idea that omega-3s keep your mind sharp as you age.
Marco: This two-year clinical trial tested exactly that. Researchers confirmed the omega-3s from fish oil supplements did reach the brain — the delivery worked. But there was no measurable improvement in memory, and no meaningful protection against cognitive decline. Two years. No benefit on those measures.
Klara: What makes this study particularly uncomfortable is that brands often hide behind bioavailability as their defence. Bioavailability means how well your body absorbs and transports an ingredient. These researchers took that argument away. The omega-3s arrived at the brain. They just didn't do anything measurable once they got there.
Marco: From a commercial angle, this is a credibility problem that won't stay quiet. Retailers like Holland & Barrett and category buyers at dm are paying attention to headlines like this. If consumers start questioning the brain health angle, that is a lot of shelf space under pressure.
Klara: I'd be cautious about drawing too wide a conclusion though. This is one trial design, one population, one dose protocol. I don't think it buries omega-3s for brain health entirely. But it does mean brands relying on vague cognitive claims — without specific clinical backing for their exact formulation — are now in a very exposed position under EU health claims rules.
Marco: That is the real lesson here. Getting an ingredient to the brain is not the same as proving a benefit. Now let's move to our next story.
Klara: Italy's advertising watchdog has just censured a magnesium supplement brand for implying it could treat restless legs and improve sleep.
Klara: The IAP — that's Italy's self-regulatory body for advertising standards — ruled against Magic Magnesium Malate. The brand's messaging suggested their product could ease leg discomfort at night and support better sleep. The IAP found that evidence behind those claims was insufficient to justify the advertising.
Klara: What's significant is the specific mechanism the IAP targeted. The brand never used the word "treatment." They used lifestyle language — softer, suggestive phrasing. The ruling says that doesn't matter. If the implied message points toward a therapeutic outcome, the standard of proof is just as high.
Marco: And this is where European marketers need to pay close attention. "Lifestyle language" has been the quiet workaround for years. Brands choose phrases like "supports comfort" or "promotes restful nights" specifically to avoid triggering formal health claim rules. This ruling shows that strategy has a ceiling.
Klara: Under EU health claims regulation — that's EC 1924/2006 — only EFSA-authorised claims are permitted. Magnesium does have some authorised claims, including a contribution to normal muscle function and psychological function. But those are carefully worded. Restless legs syndrome is a medical condition. No supplement brand is permitted to claim, directly or indirectly, that their product addresses it.
Marco: The commercial risk here is real. Italy is a significant supplement market. But more importantly, IAP rulings create a visible template. Advertising bodies across France, Germany, and the Nordics watch each other. A censure in Milan today can inform how a case is argued in Hamburg tomorrow.
Klara: Implied claims are no longer a safe harbour. Now, on to our next story.
Marco: Cymbiotika — a US supplement brand built on liposomal delivery technology — is moving aggressively into the beauty supplement space.
Marco: The brand has sold over 200 million liposomal sachets. Liposomal delivery means wrapping active ingredients in tiny fat-like particles to improve how well the body absorbs them. That track record has given Cymbiotika a strong credibility platform in the premium supplement world. Now they're pointing that platform at ingestible beauty — vitamins, minerals, and compounds marketed to support skin, hair, and nails from the inside.
Marco: The signal here is strategic. Cymbiotika isn't launching a collagen sachet and calling it a day. They're using their delivery technology as the trust mechanism — the argument being that their beauty ingredients arrive more effectively than a standard capsule. Two hundred million sachets is a compelling proof point to carry into a new category.
Marco: From a market perspective, this is a smart adjacency play. The ingestible beauty category is growing fast in the UK and across continental Europe. Brands that already own the "bioavailability" story in supplements have a head start when consumers start asking the same questions about their beauty products.
Klara: I'd want to slow down on that point though. Bioavailability credentials from a wellness supplement don't automatically transfer to a beauty outcome. Showing that your liposomal format absorbs well is not the same as showing it delivers measurable skin improvement. Those are separate clinical questions.
Marco: That's fair, but in a crowded market, delivery technology is becoming the premium differentiator. Brands without a credible formulation story are already losing ground at the top end.
Klara: The claim still has to be substantiated under EC 1924/2006. A sleek delivery mechanism is not a substitute for that.
Marco: Let's move to our final story for today.
Klara: L'Oréal's CEO has just made GLP-1 weight loss drugs a formal part of the company's commercial strategy conversation.
Klara: GLP-1 drugs — like Ozempic and Wegovy — suppress appetite and drive significant weight loss. They've moved from niche prescription use to genuine mass-market adoption across Europe and the US. When the world's largest beauty company starts publicly naming them as a force reshaping purchasing behaviour, that's not a trend piece. That's a market signal.
Klara: In a quarterly briefing, L'Oréal's CEO described GLP-1 adoption as "a very important phenomenon" for the business. The implication is clear — people losing weight rapidly are changing how they buy and think about beauty and skincare. That shift is measurable enough that it landed in an executive briefing to investors.
Marco: From a commercial standpoint, this is the clearest institutional validation the GLP-1 adjacency opportunity has received so far. Supplement and nutraceutical brands have been circling this consumer for months. L'Oréal naming it out loud means the segment is now too large to ignore, and too specific to address with generic messaging.
Klara: The nutritional case for supporting GLP-1 users is actually well-grounded. Rapid weight loss carries real risks — muscle loss, micronutrient deficiencies, skin integrity changes. Collagen, protein, B vitamins, zinc. These aren't speculative. They address documented physiological changes.
Marco: Which is exactly why brands with credible formulations and strong bioavailability stories are in a strong position here. The GLP-1 consumer is typically health-literate and willing to spend. That combination rarely appears in a new segment this size.
Klara: The regulatory caution is still essential though. No supplement brand can claim to support or complement a prescription drug. The positioning has to sit firmly in nutritional support territory — and that line needs to be drawn carefully.
Marco: Today's throughline is clear — consumer trust in supplements is harder to earn than ever, and easier to lose.
Klara: If your claims can't survive a two-year trial or a regulator's scrutiny, they won't survive the market either.
Marco: That's the standard now. Science, honesty, and proof — in that order.